Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT07938034
PHASE1

A Study of SYH2053 Injection in Participants With Renal Impairment Compared to Participants With Normal Renal Function

Sponsor: CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.

View on ClinicalTrials.gov

Summary

This study is a Phase I, single-dose, open-label trial to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of a single dose of SYH2053 injection in participants with moderate, and severe renal impairment compared to participants with normal renal function.

Official title: A Phase I Clinical Trial to Evaluate the Pharmacokinetics, Pharmacodynamics, and Safety of SYH2053 Injection in Participants With Normal Renal Function and Renal Impairment: A Non-randomized, Open-label, Parallel-Controlled, Single-Dose Study

Key Details

Gender

All

Age Range

18 Years - 75 Years

Study Type

INTERVENTIONAL

Enrollment

24

Start Date

2026-07-15

Completion Date

2027-09-15

Last Updated

2026-11-16

Healthy Volunteers

No

Interventions

DRUG

SYH2053

subcutaneous injection

Locations (1)

Peking University Third Hospital

Beijing, Beijing Municipality, China